Secondary Central Nervous System Involvement in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab Combined CHOP Therapy – a Supplementary Analysis of JCOG0601 | AMiner
Secondary Central Nervous System Involvement in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab Combined CHOP Therapy – a Supplementary Analysis of JCOG0601
Secondary central nervous system involvement (sCNSi) in diffuse large B-cell lymphoma (DLBCL) is fatal. However, its features in patients with sCNSi who are categorized as lower risk by international prognostic index (IPI) or CNS-IPI are not yet fully understood. In the present analysis, we evaluated DLBCL patients who developed sCNSi at their first progression and who participated in JCOG0601, most of whom were lower risk by IPI. Of 409 patients, 21 (5.1
更多
查看译文
关键词
Central nervous system-international prognostic index,Diffuse large B-cell lymphoma,International prognostic index,JCOG0601,Secondary central nervous system involvement